메뉴 건너뛰기




Volumn 20, Issue 10, 2014, Pages 2783-2792

Population pharmacokinetics of bevacizumab in children with osteosarcoma: Implications for dosing

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

EID: 84901003037     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2364     Document Type: Article
Times cited : (36)

References (43)
  • 1
    • 84865129521 scopus 로고    scopus 로고
    • Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
    • Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012;15:171-85.
    • (2012) Angiogenesis , vol.15 , pp. 171-185
    • Papadopoulos, N.1    Martin, J.2    Ruan, Q.3    Rafique, A.4    Rosconi, M.P.5    Shi, E.6
  • 2
    • 13444278498 scopus 로고    scopus 로고
    • Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies
    • Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65: 671-80.
    • (2005) Cancer Res , vol.65 , pp. 671-680
    • Gerber, H.P.1    Ferrara, N.2
  • 3
    • 0032806309 scopus 로고    scopus 로고
    • Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin
    • Borgstrom P, Gold DP, Hillan KJ, Ferrara N. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999; 19:4203-14.
    • (1999) Anticancer Res , vol.19 , pp. 4203-4214
    • Borgstrom, P.1    Gold, D.P.2    Hillan, K.J.3    Ferrara, N.4
  • 4
    • 18744377487 scopus 로고    scopus 로고
    • Bevacizumab in combination chemotherapy for colorectal and other cancers
    • Motl S. Bevacizumab in combination chemotherapy for colorectal and other cancers. Am J Health Syst Pharm 2005;62:1021-32.
    • (2005) Am J Health Syst Pharm , vol.62 , pp. 1021-1032
    • Motl, S.1
  • 5
    • 0037208589 scopus 로고    scopus 로고
    • Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
    • Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-5.
    • (2003) J Clin Oncol , vol.21 , pp. 60-65
    • Kabbinavar, F.1    Hurwitz, H.I.2    Fehrenbacher, L.3    Meropol, N.J.4    Novotny, W.F.5    Lieberman, G.6
  • 6
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan fluorouracil, and leucovorin for metastatic colorectal cancer
    • Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.NEngl J Med 2004;350:2335-42.
    • (2004) NEngl J Med , vol.350 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3    Cartwright, T.4    Hainsworth, J.5    Heim, W.6
  • 7
    • 20544471876 scopus 로고    scopus 로고
    • Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer
    • Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. Am J Clin Oncol 2005;23:3706-12.
    • (2005) Am J Clin Oncol , vol.23 , pp. 3706-3712
    • Kabbinavar, F.F.1    Hambleton, J.2    Mass, R.D.3    Hurwitz, H.I.4    Bergsland, E.5    Sarkar, S.6
  • 8
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
    • (2004) N Engl J Med , vol.350 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3    Cartwright, T.4    Hainsworth, J.5    Heim, W.6
  • 9
    • 49049105525 scopus 로고    scopus 로고
    • Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study
    • Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. Am J Clin Oncol 2008;26:3523-9.
    • (2008) Am J Clin Oncol , vol.26 , pp. 3523-3529
    • Hochster, H.S.1    Hart, L.L.2    Ramanathan, R.K.3    Childs, B.H.4    Hainsworth, J.D.5    Cohn, A.L.6
  • 10
    • 34248173883 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
    • Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. Am J Clin Oncol 2007;25:1539-44.
    • (2007) Am J Clin Oncol , vol.25 , pp. 1539-1544
    • Giantonio, B.J.1    Catalano, P.J.2    Meropol, N.J.3    O'Dwyer, P.J.4    Mitchell, E.P.5    Alberts, S.R.6
  • 11
    • 2942657615 scopus 로고    scopus 로고
    • Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
    • Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-91.
    • (2004) J Clin Oncol , vol.22 , pp. 2184-2191
    • Johnson, D.H.1    Fehrenbacher, L.2    Novotny, W.F.3    Herbst, R.S.4    Nemunaitis, J.J.5    Jablons, D.M.6
  • 12
    • 0042343801 scopus 로고    scopus 로고
    • A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
    • Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
    • (2003) N Engl J Med , vol.349 , pp. 427-434
    • Yang, J.C.1    Haworth, L.2    Sherry, R.M.3    Hwu, P.4    Schwartzentruber, D.J.5    Topalian, S.L.6
  • 13
    • 36849019301 scopus 로고    scopus 로고
    • Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study
    • Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. Am J Clin Oncol 2007;25:5165-71.
    • (2007) Am J Clin Oncol , vol.25 , pp. 5165-5171
    • Burger, R.A.1    Sill, M.W.2    Monk, B.J.3    Greer, B.E.4    Sorosky, J.I.5
  • 15
    • 68649114787 scopus 로고    scopus 로고
    • Safety and efficacy of bevacizumabwith hypofractionated stereotactic irradiation for recurrent malignant gliomas
    • Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, et al. Safety and efficacy of bevacizumabwith hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009;75:156-63.
    • (2009) Int J Radiat Oncol Biol Phys , vol.75 , pp. 156-163
    • Gutin, P.H.1    Iwamoto, F.M.2    Beal, K.3    Mohile, N.A.4    Karimi, S.5    Hou, B.L.6
  • 16
    • 65249185501 scopus 로고    scopus 로고
    • Bevacizumab and chemotherapy for recurrent glioblastoma: A singleinstitution experience
    • Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a singleinstitution experience. Neurology 2009;72:1217-22.
    • (2009) Neurology , vol.72 , pp. 1217-1222
    • Nghiemphu, P.L.1    Liu, W.2    Lee, Y.3    Than, T.4    Graham, C.5    Lai, A.6
  • 17
    • 18844467502 scopus 로고    scopus 로고
    • Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis
    • Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000;6:572-7.
    • (2000) Clin Cancer Res , vol.6 , pp. 572-577
    • Kaya, M.1    Wada, T.2    Akatsuka, T.3    Kawaguchi, S.4    Nagoya, S.5    Shindoh, M.6
  • 18
    • 0033166894 scopus 로고    scopus 로고
    • Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma
    • Lee YH, Tokunaga T, Oshika Y, Suto R, Yanagisawa K, Tomisawa M, et al. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer 1999;35:1089-93.
    • (1999) Eur J Cancer , vol.35 , pp. 1089-1093
    • Lee, Y.H.1    Tokunaga, T.2    Oshika, Y.3    Suto, R.4    Yanagisawa, K.5    Tomisawa, M.6
  • 19
    • 18344390219 scopus 로고    scopus 로고
    • Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma
    • Kaya M, Wada T, Kawaguchi S, Nagoya S, Yamashita T, Abe Y, et al. Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer 2002;86:864-9.
    • (2002) Br J Cancer , vol.86 , pp. 864-869
    • Kaya, M.1    Wada, T.2    Kawaguchi, S.3    Nagoya, S.4    Yamashita, T.5    Abe, Y.6
  • 22
    • 38649105118 scopus 로고    scopus 로고
    • Phase i trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A Children's Oncology Group Study
    • Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2008;26:399-405.
    • (2008) J Clin Oncol , vol.26 , pp. 399-405
    • Glade Bender, J.L.1    Adamson, P.C.2    Reid, J.M.3    Xu, L.4    Baruchel, S.5    Shaked, Y.6
  • 24
    • 24644454338 scopus 로고    scopus 로고
    • Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab
    • Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 2005;23:4853-5.
    • (2005) J Clin Oncol , vol.23 , pp. 4853-4855
    • Ellis, L.M.1    Curley, S.A.2    Grothey, A.3
  • 25
    • 0035746834 scopus 로고    scopus 로고
    • Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation
    • Howdieshell TR, Callaway D, Webb WL, Gaines MD, Procter CD Jr, Sathyanarayana, et al. Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J Surg Res 2001;96:173-82.
    • (2001) J Surg Res , vol.96 , pp. 173-182
    • Howdieshell, T.R.1    Callaway, D.2    Webb, W.L.3    Gaines, M.D.4    Procter Jr., C.D.5
  • 26
    • 0042167333 scopus 로고    scopus 로고
    • The effect of vascular endothelial growth factor on the healing of ischaemic skin wounds
    • Zhang F, Lei MP, Oswald TM, Pang Y, Blain B, Cai ZW, et al. The effect of vascular endothelial growth factor on the healing of ischaemic skin wounds. Br J Plast Surg 2003;56:334-41.
    • (2003) Br J Plast Surg , vol.56 , pp. 334-341
    • Zhang, F.1    Lei, M.P.2    Oswald, T.M.3    Pang, Y.4    Blain, B.5    Cai, Z.W.6
  • 27
    • 0036294343 scopus 로고    scopus 로고
    • Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats
    • Roman CD, Choy H, Nanney L, Riordan C, Parman K, Johnson D, et al. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res 2002;105:43-7.
    • (2002) J Surg Res , vol.105 , pp. 43-47
    • Roman, C.D.1    Choy, H.2    Nanney, L.3    Riordan, C.4    Parman, K.5    Johnson, D.6
  • 29
    • 20144380941 scopus 로고    scopus 로고
    • Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate
    • Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005;23:2004-11.
    • (2005) J Clin Oncol , vol.23 , pp. 2004-2011
    • Meyers, P.A.1    Schwartz, C.L.2    Krailo, M.3    Kleinerman, E.S.4    Betcher, D.5    Bernstein, M.L.6
  • 30
    • 0014825326 scopus 로고
    • Estimation of human body surface area from height and weight
    • Gehan EA, George SL. Estimation of human body surface area from height and weight. Cancer Chemother Rep 1970;54:225-35.
    • (1970) Cancer Chemother Rep , vol.54 , pp. 225-235
    • Gehan, E.A.1    George, S.L.2
  • 32
    • 0024309467 scopus 로고
    • Prediction of the distribution volumes of cefazolin and tobramycin in obese children based on physiological pharmacokinetic concepts
    • Koshida R, Nakashima E, Taniguchi N, Tsuji A, Benet LZ, Ichimura F. Prediction of the distribution volumes of cefazolin and tobramycin in obese children based on physiological pharmacokinetic concepts. Pharm Res 1989;6:486-91.
    • (1989) Pharm Res , vol.6 , pp. 486-491
    • Koshida, R.1    Nakashima, E.2    Taniguchi, N.3    Tsuji, A.4    Benet, L.Z.5    Ichimura, F.6
  • 33
    • 0013940160 scopus 로고
    • Total body water in obesity
    • Gundersen K, Shen G. Total body water in obesity. Am J Clin Nutr 1966;19:77-83.
    • (1966) Am J Clin Nutr , vol.19 , pp. 77-83
    • Gundersen, K.1    Shen, G.2
  • 34
    • 0028870538 scopus 로고
    • Aminoglycoside dosing weight correction factors for patients of various body sizes
    • Traynor AM, Nafziger AN, Bertino JS Jr. Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother 1995;39:545-8.
    • (1995) Antimicrob Agents Chemother , vol.39 , pp. 545-548
    • Traynor, A.M.1    Nafziger, A.N.2    Bertino Jr., J.S.3
  • 35
    • 0017029442 scopus 로고
    • Disparate hydration of adipose and lean tissue require a new model for body water distribution in man
    • Wang J, Pierson RN Jr. Disparate hydration of adipose and lean tissue require a new model for body water distribution in man. J Nutr 1976;106:1687-93.
    • (1976) J Nutr , vol.106 , pp. 1687-1693
    • Wang, J.1    Pierson Jr., R.N.2
  • 38
    • 77955662424 scopus 로고    scopus 로고
    • One size may not fit all: Pondering antibiotic dosing in obesity
    • Polotsky HN, Polotsky AJ. One size may not fit all: pondering antibiotic dosing in obesity. Maturitas 2010;66:381-2.
    • (2010) Maturitas , vol.66 , pp. 381-382
    • Polotsky, H.N.1    Polotsky, A.J.2
  • 39
    • 84859408321 scopus 로고    scopus 로고
    • Therapeutic drug monitoring to adjust dosing in morbid obesity - A new use for an old methodology
    • Martin JH, Saleem M, Looke D. Therapeutic drug monitoring to adjust dosing in morbid obesity - a new use for an old methodology. Br J Clin Pharmacol 2012;73:685-90.
    • (2012) Br J Clin Pharmacol , vol.73 , pp. 685-690
    • Martin, J.H.1    Saleem, M.2    Looke, D.3
  • 41
    • 84861396303 scopus 로고    scopus 로고
    • Development and validation of a predictive equation for lean body mass in children and adolescents
    • Foster BJ, Platt RW, Zemel BS. Development and validation of a predictive equation for lean body mass in children and adolescents. Ann Hum Biol 2012;39:171-82.
    • (2012) Ann Hum Biol , vol.39 , pp. 171-182
    • Foster, B.J.1    Platt, R.W.2    Zemel, B.S.3
  • 42
    • 16644390136 scopus 로고    scopus 로고
    • Obesity: Impediment to postsurgical wound healing
    • Wilson JA, Clark JJ. Obesity: impediment to postsurgical wound healing. Adv Skin Wound Care 2004;17:426-35.
    • (2004) Adv Skin Wound Care , vol.17 , pp. 426-435
    • Wilson, J.A.1    Clark, J.J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.